Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Non-Current Deffered Revenue (2016 - 2023)

Cartesian Therapeutics (RNAC) has disclosed Non-Current Deffered Revenue for 9 consecutive years, with $3.5 million as the latest value for Q4 2023.

  • On a quarterly basis, Non-Current Deffered Revenue changed N/A to $3.5 million in Q4 2023 year-over-year; TTM through Dec 2023 was $3.5 million, a N/A change, with the full-year FY2023 number at $3.5 million, changed N/A from a year prior.
  • Non-Current Deffered Revenue was $3.5 million for Q4 2023 at Cartesian Therapeutics, down from $4.0 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $51.5 million in Q3 2020 to a low of $3.5 million in Q4 2023.
  • A 5-year average of $16.4 million and a median of $14.7 million in 2019 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: skyrocketed 243.54% in 2020, then crashed 72.9% in 2022.
  • Cartesian Therapeutics' Non-Current Deffered Revenue stood at $14.7 million in 2019, then soared by 163.94% to $38.7 million in 2020, then crashed by 70.53% to $11.4 million in 2021, then plummeted by 52.39% to $5.4 million in 2022, then crashed by 34.92% to $3.5 million in 2023.
  • Per Business Quant, the three most recent readings for RNAC's Non-Current Deffered Revenue are $3.5 million (Q4 2023), $4.0 million (Q3 2023), and $4.9 million (Q2 2023).